Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5306 participants
OBSERVATIONAL
2016-10-31
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds
NCT05032053
Novel Oral Anticoagulants in Stroke Patients
NCT02353585
Anticoagulant-associated Intracranial Hemorrhage
NCT06168838
Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
NCT02866838
Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation
NCT02147444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Any oral antithrombotics (antiplatelets or anticoagulants)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are able to receive MRI
* Provision of written informed consent either directly or by a suitable surrogate
Exclusion Criteria
* Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Japan Agency for Medical Research and Development
OTHER_GOV
National Cerebral and Cardiovascular Center, Japan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kazunori Toyoda
Director and Chair, Department of Stroke and Cerebrovascular Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cerebral and Cardiovascular Center
Suita, Osaka, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
St. Marianna University
Kawasaki, , Japan
Kobe City Medical Center General Hospital
Kobe, , Japan
National Hospital Organization Nagoya Medical Center
Nagoya, , Japan
Saga University
Saga, , Japan
Tokushima University
Tokushima, , Japan
Juntendo University
Tokyo, , Japan
Kyorin University
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Koga M, Yoshimura S, Hasegawa Y, Shibuya S, Ito Y, Matsuoka H, Takamatsu K, Nishiyama K, Todo K, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Yagita Y, Kario K, Shiozawa M, Sato S, Yamagami H, Arihiro S, Toyoda K; SAMURAI Study Investigators. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation. Stroke. 2016 Oct;47(10):2582-8. doi: 10.1161/STROKEAHA.116.013746. Epub 2016 Aug 16.
Takagi M, Tanaka K, Miwa K, Sasaki M, Koga M, Hirano T, Kamiyama K, Yagita Y, Nagakane Y, Hoshino H, Terasaki T, Yakushiji Y, Kudo K, Ihara M, Yoshimura S, Yamaguchi Y, Shiozawa M, Toyoda K; for BAT2 Investigators. The bleeding with antithrombotic therapy study 2: Rationale, design, and baseline characteristics of the participants. Eur Stroke J. 2020 Dec;5(4):423-431. doi: 10.1177/2396987320960618. Epub 2020 Sep 24.
Tanaka K, Miwa K, Takagi M, Sasaki M, Yakushiji Y, Kudo K, Shiozawa M, Tanaka J, Nishihara M, Yamaguchi Y, Fujita K, Honda Y, Kawano H, Ide T, Yoshimura S, Koga M, Hirano T, Toyoda K. Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2. J Am Heart Assoc. 2022 Mar 15;11(6):e024749. doi: 10.1161/JAHA.121.024749. Epub 2022 Mar 5.
Miwa K, Tanaka K, Koga M, Tanaka K, Yakushiji Y, Sasaki M, Kudo K, Shiozawa M, Yoshimura S, Ihara M, Fujimoto S, Hoshino H, Kamiyama K, Kawano H, Nagasawa H, Nagakane Y, Nishiyama K, Yagita Y, Yoshimura S, Hirano T, Toyoda K; BAT2 Investigators. Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features. Stroke. 2025 Sep;56(9):2605-2616. doi: 10.1161/STROKEAHA.125.050859. Epub 2025 Jun 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000023669
Identifier Type: OTHER
Identifier Source: secondary_id
16ek0210055h
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.